| Title: | Serum metabolomics improves risk stratification for incident heart failure |
| Journal: | European Journal of Heart Failure |
| Published: | 16 Apr 2024 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/38623713/ |
| DOI: | https://doi.org/10.1002/ejhf.3226 |
| URL: | https://www.medrxiv.org/content/medrxiv/early/2023/08/23/2023.08.21.23294202.full.pdf |
| Citations: | 1 (1 in last 2 years) as of 8 Aug 2024 |
Publication 9892
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
AIMS: Prediction and early detection of heart failure (HF) is crucial to mitigate its impact on quality of life, survival, and healthcare expenditure. Here, we explored the predictive value of serum metabolomics (168 metabolites detected by proton nuclear magnetic resonance [1H-NMR] spectroscopy) for incident HF.</p>
METHODS AND RESULTS: Leveraging data of 68 311 individuals and >0.8 million person-years of follow-up from the UK Biobank cohort, we (i) fitted per-metabolite Cox proportional hazards models to assess individual metabolite associations, and (ii) trained and validated elastic net models to predict incident HF using the serum metabolome. We benchmarked discriminative performance against a comprehensive, well-validated clinical risk score (Pooled Cohort Equations to Prevent HF [PCP-HF]). During a median follow-up of ≈12.3 years, several metabolites showed independent association with incident HF (90/168 adjusting for age and sex, 48/168 adjusting for PCP-HF). Performance-optimized risk models effectively retained key predictors representing highly correlated clusters (≈80% feature reduction). Adding metabolomics to PCP-HF improved predictive performance (Harrel's C: 0.768 vs. 0.755, ΔC = 0.013, [95% confidence interval [CI] 0.004-0.022], continuous net reclassification improvement [NRI]: 0.287 [95% CI 0.200-0.367], relative integrated discrimination improvement [IDI]: 17.47% [95% CI 9.463-27.825]). Models including age, sex and metabolomics performed almost as well as PCP-HF (Harrel's C: 0.745 vs. 0.755, ΔC = 0.010 [95% CI -0.004 to 0.027], continuous NRI: 0.097 [95% CI -0.025 to 0.217], relative IDI: 13.445% [95% CI -10.608 to 41.454]). Risk and survival stratification was improved by integrating metabolomics.</p>
CONCLUSION: Serum metabolomics improves incident HF risk prediction over PCP-HF. Scores based on age, sex and metabolomics exhibit similar predictive power to clinically-based models, potentially offering a cost-effective, standardizable, and scalable single-domain alternative.</p>
13 Keywords
- Aged
- Biomarkers
- Female
- Follow-Up Studies
- Heart Failure
- Humans
- Incidence
- Male
- Metabolomics
- Middle Aged
- Predictive Value of Tests
- Risk Assessment
- United Kingdom
8 Authors
- Rafael R. Oexner
- Hyunchan Ahn
- Konstantinos Theofilatos
- Ravi A. Shah
- Robin Schmitt
- Philip Chowienczyk
- Anna Zoccarato
- Ajay M. Shah
1 Application
| Application ID | Title |
|---|---|
| 98729 | Mechanisms of cardiac remodeling |
Enabling scientific discoveries that improve human health